Intravenous Acyclovir-Associated Acute Kidney Injury in Pediatric Patients: A Retrospective Study
Innovative Journal of Pediatrics · 16.04.2026 · 36 (2)
DOI: 10.5812/ijpediatr-168331 ↗Kurz gefasst
Fachartikel in der Zeitschrift Innovative Journal of Pediatrics, online erschienen am 16.04.2026. Verfasst von Abdulrahman Alotaibi und 8 weiteren Autor:innen. Die Arbeit nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Acyclovir is widely used to manage herpesvirus infections in pediatric populations but is associated with potential nephrotoxicity, particularly in intravenous formulations. Limited local data are available on the incidence and risk factors of acyclovir-induced acute kidney injury (AKI) in children in Saudi Arabia.
Objectives
To assess the incidence of AKI among hospitalized pediatric patients receiving intravenous acyclovir and evaluate the impact of hydration protocols and co-administered nephrotoxic agents.
Methods
This retrospective cohort study was conducted at King Abdullah Specialized Children’s Hospital, including pediatric inpatients under 14 years of age who received IV acyclovir between June 2020 and December 2023. The most common acyclovir dose was 10 mg/kg (44%), and the median treatment duration was 4 days (range 2 - 77). Patients were managed in the Neonatal Intensive Care Unit (NICU), Pediatric Intensive Care Unit (PICU), or general pediatric wards according to clinical severity. Patients with pre-existing kidney disease, missing creatinine values, or short-duration therapy were excluded. Demographic, clinical, laboratory, and medication data were extracted from electronic medical records. Acute kidney injury was defined according to Kidney Disease: Improving Global Outcomes (KDIGO) criteria. Hydration levels and concurrent nephrotoxic drug exposure were analyzed.
Results
A total of 100 patients were included, with a median age of 22.5 months. The majority received maintenance intravenous fluids (IVF) hydration, and 37% received IV fluids throughout the acyclovir treatment course. Despite 59% of patients receiving at least one nephrotoxic medication, only one case of AKI was identified (1.0%; 95% CI, 0.03 - 5.45%). The most commonly co-administered nephrotoxic agent was vancomycin. No significant decline in estimated glomerular filtration rate (eGFR) or elevation in serum creatinine was observed across the cohort.
Conclusions
The incidence of AKI was low among pediatric inpatients receiving IV acyclovir. Because of the very low event rate and lack of a comparison group, causal conclusions regarding the effect of hydration cannot be made. Further multicenter studies are warranted to better define risk factors and preventive strategies.
Zitieren
APA
Alotaibi, A., Alsaleh, N. A., Alsmari, A., Muqati, H. A., Alenazi, R., Boushal, M. A., Almutairi, O., Nahari, M., & Alnuhait, M. (2026). Intravenous Acyclovir-Associated Acute Kidney Injury in Pediatric Patients: A Retrospective Study. Innovative Journal of Pediatrics, 36(2). https://doi.org/10.5812/ijpediatr-168331
Vancouver
Alotaibi A, Alsaleh NA, Alsmari A, Muqati HA, Alenazi R, Boushal MA, et al. Intravenous Acyclovir-Associated Acute Kidney Injury in Pediatric Patients: A Retrospective Study. Innovative Journal of Pediatrics. 2026;36(2). doi:10.5812/ijpediatr-168331
BibTeX
@article{Alotaibi2026,
author = {Alotaibi, Abdulrahman and Alsaleh, Nada A. and Alsmari, Abeer and Muqati, Hessa Al and Alenazi, Raghad and Boushal, Muneerah Al and Almutairi, Ohoud and Nahari, Majed and Alnuhait, Mohammed},
title = {Intravenous Acyclovir-Associated Acute Kidney Injury in Pediatric Patients: A Retrospective Study},
journal = {Innovative Journal of Pediatrics},
year = {2026},
volume = {36},
number = {2},
doi = {10.5812/ijpediatr-168331}
}
EUVIMED